BRIEF published on 06/10/2026 at 07:35, 8 days 18 hours ago Sensorion Advances SENS-601 pour la perte auditive liée au gène GJB2 Essais Cliniques Thérapie Génique Sensorion SENS-601 Perte Auditive GJB2
BRIEF published on 06/10/2026 at 07:35, 8 days 18 hours ago Sensorion Advances SENS-601 for GJB2-Related Hearing Loss Clinical Trials Gene Therapy Sensorion SENS-601 GJB2 Hearing Loss
BRIEF published on 06/10/2026 at 07:35, 8 days 18 hours ago Sensorion Refocuses on SENS-601 for Gene Therapy Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 06/10/2026 at 07:35, 8 days 18 hours ago Sensorion se Recentre sur SENS-601 pour la Thérapie Génique Essais Cliniques Thérapie Génique Sensorion Perte Auditive SENS-601
PRESS RELEASE published on 06/10/2026 at 07:30, 8 days 18 hours ago Inside Information / Other news releases Sensorion achieves key regulatory milestones for SENS-601 addressing GJB2-related hearing loss and discontinues SENS-501. Fast Track procedure granted by ANSM in France. Clinical trials planned in Canada and U.S. IND submission targeted by 2026 Clinical Trials Gene Therapy Sensorion Regulatory Milestones GJB2-related Hearing Loss
PRESS RELEASE published on 06/10/2026 at 07:30, 8 days 18 hours ago Informations privilégiées / Autres communiqués Sensorion franchit des étapes réglementaires clés pour SENS-601 dans la perte auditive liée au gène GJB2 et le sélectionne comme principal candidat-médicament en thérapie génique Thérapie Génique Sensorion Perte Auditive SENS-601 Gène GJB2
BRIEF published on 05/18/2026 at 07:35, 1 month ago Fred Chereau nommé Directeur Général de Sensorion Direction Générale Thérapie Génique Sensorion Fred Chereau Pertes D'audition
BRIEF published on 05/18/2026 at 07:35, 1 month ago Sensorion Appoints Fred Chereau as CEO Biotechnology CEO Appointment Gene Therapy Sensorion Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 1 month ago Sensorion nomme Fred Chereau au poste de PDG Biotechnologie Thérapie Génique Nomination Du PDG Sensorion Fred Chereau
BRIEF published on 05/18/2026 at 07:35, 1 month ago Fred Chereau appointed Managing Director of Sensorion Gene Therapy General Management Hearing Loss Sensory Fred Chereau
Published on 06/19/2026 at 01:20, 28 minutes ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 41 minutes ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/19/2026 at 00:00, 1 hour 48 minutes ago Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/18/2026 at 23:55, 1 hour 53 minutes ago Relevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board Member
Published on 06/19/2026 at 01:15, 32 minutes ago UV Laser Technology Gains Momentum in Europe for Clean, Cold Marking and High-Precision Engraving
Published on 06/18/2026 at 22:35, 3 hours 12 minutes ago Bitmine Immersion Technologies Announces Cash Dividend of $0.1056 per Share of 9.50% Series A Perpetual Preferred Stock
Published on 06/18/2026 at 22:00, 3 hours 48 minutes ago Blue Cap AG: Closing of the Acquisition of Janoschka AG Successfully Completed
Published on 06/18/2026 at 18:00, 7 hours 48 minutes ago Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 mai 2026
Published on 06/18/2026 at 18:00, 7 hours 48 minutes ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 8 hours 3 minutes ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:45, 8 hours 3 minutes ago EURAZEO INVESTIT DANS LAURALU, ACTEUR PANEUROPÉEN SPÉCIALISTE DES INFRASTRUCTURES INDUSTRIELLES DÉPLOYABLES
Published on 06/18/2026 at 17:45, 8 hours 3 minutes ago ASSEMBLEE GENERALE DU 16 JUIN 2026 : COMPTE-RENDU ET RESULTATS DES VOTES
